Preserved liver function, portal thrombosis and absence of oesophageal varices are risk factors for metastasis of hepatocellular carcinoma

Digestive and Liver Disease

Volumn 43, Issue 4, 2011, Pages 319-324

  Addario, Luigi ^a   Tritto, Giovanni ^a,b   Cavaglià, Enrico ^a   Amodio, Francesco ^a   Giannelli, Eduardo ^a   Di Costanzo, Giovan Giuseppe ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Hepatocellular carcinoma; Liver cirrhosis; Metastasis; Oesophageal varices; Portal thrombosis

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; BILIRUBIN; HEPATITIS C ANTIBODY;

ABSENCE OF ESOPHAGEAL VARICES; ADULT; AGED; ALCOHOLISM; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD LEVEL; CANCER DIAGNOSIS; CHEMOEMBOLIZATION; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISTANT METASTASIS; ECHOGRAPHY; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; INJECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER METASTASIS; LIVER TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS ALCOHOL INJECTION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TRANSARTERIAL CHEMOEMBOLIZATION; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PORTAL VEIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VENOUS THROMBOSIS;

EID: 79952185967     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.09.003     Document Type: Article

References (37)

1. Bosch F.X., Ribes J., Diaz M., et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127(Suppl. 1):S5-S16.
2. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127(Suppl. 1):S27-S34.
3. Marrero J.A., Fontana R.J., Su G.L., et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-1354.
4. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
5. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56:918-928.
6. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000, 31:840-845. The Cancer of the Liver Italian Program (CLIP) Investigators.
7. Pugh R.N., Murray-Lyon I.M., Dawson Jl, et al. Transection of the oesophagus for bleeding ooesophageal varices. Br J Surg 1973, 60:646-649.
8. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
9. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329.
10. Matsumoto Y., Suzuki T., Asada I., et al. Clinical classification of hepatoma in Japan according to serial changes in serum alpha-fetoprotein levels. Cancer 1982, 49:354-360.
11. Edmondson H.A., Steiner P.E. Primary carcinoma of the liver. A study of 100 cases among 4900 necropsies. Cancer 1954, 7:462-503.
12. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 11:693-699.
13. Stigliano R., Marelli L., Yu D., et al. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treatm Rev 2007, 33:437-447.
14. Imamura J., Tateishi R., Shiina S., et al. Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol 2008, 103:3057-3062.
15. Uka K., Aikata H., Takaki S., et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007, 13:414-420.
16. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
17. Katyal S., Oliver J.H., Peterson M.S., et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000, 216:698-703.
18. Natsuizaka M., Omura T., Akaike T., et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 2005, 20:1781-1787.
19. Kanda M., Tateishi R., Yoshida H., et al. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int 2008, 28:1183-1185.
20. Lee Y.T., Geer D.A. Primary liver cancer: pattern of metastases. J Surg Oncol 1987, 36:26-31.
21. Yoon K.T., Kim J.K., Kim do Y., et al. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastases in pretreatment staging of hepatocellular carcinoma. Oncology 2007, 72(Suppl. 1):S104-S110.
22. Kawaoka T., Aikata H., Takaki S., et al. FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res 2009, 39:134-142.
23. Marrero J.A., Fontana R.J., Barrat, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005, 41:707-716.
24. Henderson J., Sherman M., Tavill A., et al. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB: Off J Hepatico-Pancreatico-Biliary Assoc (Oxford) 2003, 5:243-250.
25. Huo T.I., Huang Y.H., Lin H.C., et al. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 2006, 101:975-982.
26. Orlando A., Leandro G., Olivo M., et al. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009, 104:514-524.
27. Ganne-Carriè N., Chastang C., Chapel C., et al. Predictive Score for the Development of Hepatocellular Carcinoma and additional value of liver large cell dysplasia in western patients with chirrosis. Hepatology 1996, 23:1112-1118.
28. Ikeda K., Saitoh S., Koida I., et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993, 18:47-53.
29. Ohnishi K., Chin N., Saito M., et al. Portographic opacification of hepatic veins and (anomalous) anastomoses between the portal and hepatic veins in cirrhosis-indication of extensive intra-hepatic shunts. Am J Gastroenterol 1986, 81:975-978.
30. El-Serag H., Richardson P.A., Everhart J.E. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001, 96:2462-2467.
31. Rahman M.A., Dhar D.K., Yamaguchi E., et al. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 2001, 7:1325-1332.
32. Di Costanzo G.G., De Luca M., Tritto G., et al. Effect of alcohol, cigarette smoking, and diabetes on occurrence of hepatocellular carcinoma in patients with transfusion-acquired hepatitis C virus infection who develop cirrhosis. Eur J Gastroenterol Hepatol 2008, 20:674-679.
33. Silva M.A., Hegab B., Hyde C., et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008, 57:1592-1596.
34. Yuki K., Hirohashi S., Sakamoto M., et al. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 1990, 66:2174-2179.
35. Kaibori M., Matsui Y., Yanagida H., et al. Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma. World J Surg 2004, 28:702-707.
36. Hu K.Q., Kyulo N.L., Lim N., et al. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 2004, 99:860-865.
37. Arguedas M.R., Chen V.K., Eloubeidi M.A., et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003, 98:679-690.